Abstract
Objectives: To investigate regional differences in cerebral glucose metabolism and blood flow of dementia with Lewy bodies (DLB), we studied 7 subjects with DLB and 20 normal controls using F-18 fiuorodeoxyglucose (FDG) and positron emission tomography (PET) and then examined the same 7 subjects and 20 other normal controls with I-123 iodoamphetamine (IMP) and single photon emission computed tomography (SPECT).Methods: The anatomically standardized images were produced with NEUROSTAT and the regional relative metabolic and perfusional values were calculated.Results: The mean reduction ratios of FDG uptake in the DLB group relative to the mean normal controls in the parietal lobe and occipital lobe were 0.72 and 0.83, respectively, while the corresponding mean reduction ratios of IMP uptake were 0.81 and 0.88, respectively. In the DLB group, parietal FDG uptake was significantly lower than parietal IMP uptake (p < 0.05), occipital FDG uptake was significantly lower than occipital IMP uptake (p < 0.05), and parietal IMP uptake was significantly lower than occipital IMP uptake (p < 0.01), but there was no difference between parietal and occipital FDG uptake.Conclusions: Our findings suggest that parietal metabolism and perfusion are severely affected in DLB patients, though the occipital metabolic and perfusional reduction is thought to be a feature of DLB. FDG-PET is thought to be superior to IMP-SPECT in detecting functional changes in the DLB brain.
This is a preview of subscription content, log in via an institution to check access.
REFERENCES
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop.Neurology 1996; 47: 1113–1124.
Albin RL, Minoshima S, D’Amato CJ, Frey KA, Kuhl DA, Sima AAF. Fluorodeoxyglucose positron emission tomography in diffuse Lewy body disease.Neurology 1996; 47: 462–466.
Imamura T, Ishii K, Sasaki M, Kitagaki H, Yamaji S, Hirono N, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease: a comparative study using positron emission tomography.Neurosci Lett 1997; 235: 49–52.
Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease.Neurology 1998; 51: 125–130.
Ishii K, Yamaji S, Kitagaki H, Imamura T, Hirono N, Mori E. Regional cerebral blood flow difference between dementia with Lewy bodies and AD.Neurology 1999; 53: 413–416.
Colloby SJ, Fenwick JD, Williams ED, Paling SM, Lobotesis K, Ballard C, et al. A comparison of99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer’s disease using statistical parametric mapping.Eur J Nucl Med Mol Imaging 2002; 29: 615–622.
Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer’s disease.J Nucl Med 1997; 38: 925–928.
Ishii K, Mori E, Kitagaki H, Sakamoto S, Yamaji S, Imamura T, et al. The clinical utility of visual evaluation of scintigraphic perfusion for Alzheimer’s disease using123I-IMP SPECT.Clin Nucl Med 1996; 21: 106–110.
Ishii K, Willoch F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, et al. Statistical brain mapping of18F-FDG PET in Alzheimer’s disease: Validation of anatomic standardization for atrophied brains.J Nucl Med 2001 ; 42: 548–557.
Ishii K. Clinical application of positron emission tomography for diagnosis of dementia.Ann Nucl Med 2002; 16: 515–525.
Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J, Yonekura Y, et al. Altered cerebral energy metabolism in Alzheimer’s disease: A PET study.J Nucl Med 1994; 35: 1–6.
Loessner A, Alavi A, Lewandrowski K-U, Mozley D, Souder E, Gur RE. Regional cerebral function determined by FDG-PET in healthy volunteers: Normal patterns and changes with age.J Nucl Med 1995; 36: 1141–1149.
Bentourkia M, Bol A, Ivanoiu A, Labar D, Sibomana M, Coppens A, et al. Comparison of regional cerebral blood flow and glucose metabolism in the normal brain: effect of aging.J Neurol Sci 2000; 181: 19–28.
Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, et al. The metabolic topography of normal aging.J Cereb Blood Flow Metab 1996; 16: 385–398.
Kawachi T, Ishii K, Sakamoto S, Matsui M, Mori T, Sasaki M. Gender differences in cerebral glucose metabolism: a PET study.J Neurol Sci 2002; 199: 79–83.
Marchai G, Rioux P, Petit-Taboue MC, Sette G, Travere JM, Le Poec C, et al. Regional cerebral oxygen consumption, blood flow, and blood volume in healthy human aging.Arch Neurol 1992; 49: 1013–1020.
Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD.Neurology 2001; 56: 643–649.
Kosaka K. Diffuse Lewy body disease.Neuropathology 2000; 20 Suppl: S73-S78.
Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree—a new disease?Clin Neuropathol 1984; 3: 185–192.
Dickson DW, Crystal H, Mattiace LA, Kress Y, Schwagerl A, Ksiezak-Reding H, et al. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques.Acta Neuropathol 1989; 78: 572–584.
Gibb WR, Luthert PJ, Janota I, Lantos PL. Cortical Lewy body dementia: clinical features and classification.J Neurol Neurosurg Psychiatry 1989; 52: 185–192.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ishii, K., Hosaka, K., Mori, T. et al. Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Ann Nucl Med 18, 447–451 (2004). https://doi.org/10.1007/BF02984489
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02984489